
    
      This study will be conducted in two parts: a safety, efficacy and PD response part using two
      different drug delivery methods and an expansion cohort.

      All patients will be administered with anti-PD-1 once every 4 weeks for up to 1 year
      commencing on Day 1 and with EVX-02 vaccine as soon as it is produced.

      Part 1 will consist of two cohorts:

      Cohort A: Will receive EVX- 02A delivered by delivery methodology 1. Cohort B: Will receive
      EVX- 02B delivered by delivery device 2. Part 2 (Cohort C) will be an expansion cohort. In
      this part, only one delivery methods, either EVX-02A or EVX-02B with will be used.
    
  